Sign up
Pharma Capital

FYI Resources results confirm high-purity alumina potential for Cadoux kaolin

Analysis of final results from a drilling campaign show feedstock can be used to produce HPA of 99.99% or greater.
Kaolin mineral samples at the Cadoux Kaolin Project in Western Australia
Samples from drilling at the Cadoux Kaolin Project in Western Australia

FYI Resources Ltd (ASX:FYI) has served up final results from a drilling campaign at its Cadoux Kaolin Project in Western Australia, with the analysis confirming the resource is suitable for producing high-purity alumina (HPA).

The company said the delayed analysis supported its view the kaolin resource had the characteristics to be used as feedstock in producing HPA of 99.99% or greater, using its evolving process flowsheet.

Pre-feasibility study progresses

FYI drilled 1,613 metres during its 75-hole reverse circulation drilling campaign.

The company said work on the production flowsheet continued to progress well and technical achievements had exceeded the pre-feasibility study managers’ expectations.

READ: FYI Resources confirms kaolin resource suitable for high-purity alumina feedstock

FYI managing director Roland Hill said he was pleased with the quality of the latest results which would feed into the company’s development strategy.

“The balance of the analysis for the RC drilling is consistent with previous campaign results,” he said.

“This continues to support our opinion on the very favourable characteristics of the Cadoux deposit as a source of feedstock for the innovative HPA flowsheet we are developing.”

Hill said an understanding of the project’s geology and mineralogy would prove fundamental to the success of the company’s efforts to produce HPA.

FYI ambitions

FYI aims to become a significant producer of 4N-grade HPA as consumers adopt LED technologies, purchase electric vehicles, and buy up new smartphones and television screens.

The company hopes the quality of the aluminous clays at Cadoux deposit will mean its project will be world-class.

View full FYI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.